| Autor: |
Borrego EA; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Guerena CD; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Schiaffino Bustamante AY; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Gutierrez DA; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Valenzuela CA; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Betancourt AP; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Varela-Ramirez A; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA., Aguilera RJ; The Border Biomedical Research Center, The University of Texas El Paso, El Paso, TX 79968, USA.; Department of Biological Sciences, The University of Texas El Paso, El Paso, TX 79968, USA. |
| Abstrakt: |
In this study, we screened a chemical library to find potent anticancer compounds that are less cytotoxic to non-cancerous cells. This study revealed that pyrazole PTA-1 is a potent anticancer compound. Additionally, we sought to elucidate its mechanism of action (MOA) in triple-negative breast cancer cells. Cytotoxicity was analyzed with the differential nuclear staining assay (DNS). Additional secondary assays were performed to determine the MOA of the compound. The potential MOA of PTA-1 was assessed using whole RNA sequencing, Connectivity Map (CMap) analysis, in silico docking, confocal microscopy, and biochemical assays. PTA-1 is cytotoxic at a low micromolar range in 17 human cancer cell lines, demonstrating less cytotoxicity to non-cancerous human cells, indicating a favorable selective cytotoxicity index (SCI) for the killing of cancer cells. PTA-1 induced phosphatidylserine externalization, caspase-3/7 activation, and DNA fragmentation in triple-negative breast MDA-MB-231 cells, indicating that it induces apoptosis. Additionally, PTA-1 arrests cells in the S and G2/M phases. Furthermore, gene expression analysis revealed that PTA-1 altered the expression of 730 genes at 24 h (198 upregulated and 532 downregulated). A comparison of these gene signatures with those within CMap indicated a profile similar to that of tubulin inhibitors. Subsequent studies revealed that PTA-1 disrupts microtubule organization and inhibits tubulin polymerization. Our results suggest that PTA-1 is a potent drug with cytotoxicity to various cancer cells, induces apoptosis and cell cycle arrest, and inhibits tubulin polymerization, indicating that PTA-1 is an attractive drug for future clinical cancer treatment. |
